What are the main side effects of Eptifibatide?

Eptifibatide side effects and warning signals include Bleeding (major and minor), Thrombocytopenia, Hypotension, Back pain, and Nausea.

What evidence level is Eptifibatide?

Eptifibatide is rated Level A; the listed research status is FDA Approved.

Healing & Recovery / Level A / FDA Approved / Last reviewed 2026-04-04

Eptifibatide Evidence Guide

Eptifibatide (Integrilin) is FDA-approved for acute coronary syndrome and PCI with Phase 3 evidence from the PURSUIT and ESPRIT trials demonstrating reduced composite ischemic endpoints. As a cyclic RGD peptide GP IIb/IIIa inhibitor, it provides potent antiplatelet effect during percutaneous intervention. A well-established cardiovascular drug with a clear, validated indication.

Our Take

Best for: Acute coronary syndrome management, PCI antiplatelet therapy, GP IIb/IIIa inhibition research
Evidence grade: Level A
Confidence: High
Starting point: 180mcg/kg IV bolus then 2mcg/kg/min infusion for 18-24 hours (ACS/PCI dosing)

Benefits and Evidence

Acute Coronary Syndrome: Level A, includes human evidence - PURSUIT trial (10,948 patients) showed significant reduction in death or myocardial infarction at 30 days when added to standard therapy in unstable angina/NSTEMI.
PCI Outcomes: Level A, includes human evidence - ESPRIT trial demonstrated significant reduction in ischemic events when used during percutaneous coronary intervention with stenting.
Bleeding Risk: Level A, includes human evidence - Increased risk of bleeding complications, particularly at vascular access sites. Major bleeding rates approximately 1-3% higher than placebo in clinical trials.

Side Effects and Warnings

Bleeding (major and minor)
Thrombocytopenia
Hypotension
Back pain
Nausea
Contraindicated with active internal bleeding or recent surgery
Severe thrombocytopenia (<100,000/mm3) - discontinue immediately
Renal dose adjustment required (CrCl <50 mL/min)

Research Dosage References

<strong>Intravenous bolus + infusion</strong> - 180 mcg/kg bolus, then 2 mcg/kg/min - Continuous infusion for up to 72 hours (ACS) or 18-24 hours post-PCI - For PCI: double bolus (180 mcg/kg at time 0, repeat at 10 min). Reduce infusion to 1 mcg/kg/min if CrCl <50 mL/min.

Mechanism of Action

Eptifibatide prevents platelet aggregation through glycoprotein receptor blockade: 1. GP IIb/IIIa receptor antagonism: Reversibly binds to the glycoprotein IIb/IIIa receptor on activated platelets, preventing fibrinogen and von Willebrand factor cross-linking. 2. KGD mimicry: The Lys-Gly-Asp sequence mimics the binding domain of fibrinogen, competitively blocking the final common pathway of platelet aggregation. 3. Rapid onset and offset: Short half-life allows rapid restoration of platelet function after discontinuation, providing a controllable antiplatelet effect.

Legal Status

FDA-approved for acute coronary syndrome and percutaneous coronary intervention. Available by prescription for hospital use only. Marketed as Integrilin by Merck.